The proposed approach of predicting amyloid and/or tau pathology biomarkers from MRI data and subsequently transferring the MRI‐derived amyloid and/or tau pathology models to predict future risk of AD progression may be useful to assist in disease screening, triage of patients for invasive testing, and efficiently determining suitability for clinical trial recruitment. The gene discussed is MAPT; the disease is Alzheimer disease.